NASDAQ:CHRS Coherus BioSciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.20 -0.15 (-2.04%) (As of 06/29/2022 11:09 AM ET) Add Compare Share Today's Range$7.11▼$7.2850-Day Range$5.86▼$10.1052-Week Range$5.60▼$19.32Volume10,798 shsAverage Volume972,844 shsMarket Capitalization$557.45 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CHRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CHRS Stock Forecast (MarketRank)Overall MarketRank™2.16 out of 5 starsMedical Sector414th out of 1,433 stocksBiological Products, Except Diagnostic Industry65th out of 217 stocksAnalyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingCoherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Coherus BioSciences has a forecasted upside of 158.5% from its current price of $7.35.Amount of Analyst CoverageCoherus BioSciences has only been the subject of 3 research reports in the past 90 days. Previous Next 4.4 Community Rank Outperform VotesCoherus BioSciences has received 417 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCoherus BioSciences has received 216 “underperform” votes. (Add your “underperform” vote.)Community SentimentCoherus BioSciences has received 65.88% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Coherus BioSciences and other stocks. Vote “Outperform” if you believe CHRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CHRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCoherus BioSciences does not currently pay a dividend.Dividend GrowthCoherus BioSciences does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Coherus BioSciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.85% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Coherus BioSciences are expected to grow in the coming year, from ($3.77) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coherus BioSciences is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coherus BioSciences is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoherus BioSciences has a P/B Ratio of 5.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Coherus BioSciences (NASDAQ:CHRS)Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More CHRS Stock News HeadlinesJune 27, 2022 | finance.yahoo.comSwedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?June 18, 2022 | americanbankingnews.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Receives $19.00 Consensus PT from AnalystsJune 14, 2022 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Now Covered by UBS GroupJune 12, 2022 | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Hits New 52-Week Low at $6.93May 27, 2022 | seekingalpha.comCoherus: Will Its Chinese Gambit Fail?May 11, 2022 | finance.yahoo.comCoherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of DirectorsMay 11, 2022 | finance.yahoo.comShareholders in Coherus BioSciences (NASDAQ:CHRS) have lost 61%, as stock drops 12% this past weekMay 10, 2022 | finance.yahoo.comCoherus BioSciences Management to Present at Upcoming Investor ConferencesMay 7, 2022 | finance.yahoo.comCoherus BioSciences (CHRS) Q1 2022 Earnings Call TranscriptMay 6, 2022 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q1 2022 Earnings Call TranscriptMay 5, 2022 | apnews.comCoherus BioSciences Reports First Quarter 2022 ResultsMay 5, 2022 | finance.yahoo.comCoherus BioSciences Appoints Charlie Newton to Board of DirectorsMay 4, 2022 | seekingalpha.comCoherus BioSciences Q1 consensus EPS, revenue estimates downSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CHRS CUSIPN/A CIK1512762 Webwww.coherus.com Phone(650) 649-3530FaxN/AEmployees332Year Founded2010Company Calendar Last Earnings5/05/2022Today6/29/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+163.9%Consensus RatingModerate Buy Rating Score (0-4)2.6 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.730010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-287.10 million Net Margins-69.24% Pretax Margin-69.24% Return on Equity-211.68% Return on Assets-30.54% Debt Debt-to-Equity Ratio33.47 Current Ratio3.33 Quick Ratio3.09 Sales & Book Value Annual Sales$326.55 million Price / Sales1.71 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book5.67Miscellaneous Outstanding Shares77,423,000Free Float68,202,000Market Cap$557.45 million OptionableOptionable Beta1.22 Social Links Coherus BioSciences Frequently Asked Questions Should I buy or sell Coherus BioSciences stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Coherus BioSciences stock. View analyst ratings for Coherus BioSciences or view top-rated stocks. What is Coherus BioSciences' stock price forecast for 2022? 5 Wall Street research analysts have issued 1 year price targets for Coherus BioSciences' shares. Their CHRS stock forecasts range from $7.00 to $30.00. On average, they expect Coherus BioSciences' stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 162.1% from the stock's current price. View analysts' price targets for Coherus BioSciences or view top-rated stocks among Wall Street analysts. How has Coherus BioSciences' stock price performed in 2022? Coherus BioSciences' stock was trading at $15.96 at the beginning of 2022. Since then, CHRS shares have decreased by 54.6% and is now trading at $7.25. View the best growth stocks for 2022 here. When is Coherus BioSciences' next earnings date? Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Coherus BioSciences. How were Coherus BioSciences' earnings last quarter? Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its earnings results on Thursday, May, 5th. The biotechnology company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by $0.44. The biotechnology company earned $60.12 million during the quarter, compared to analysts' expectations of $68.07 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 211.68% and a negative net margin of 69.24%. View Coherus BioSciences' earnings history. Who are Coherus BioSciences' key executives? Coherus BioSciences' management team includes the following people: Mr. Dennis M. Lanfear, Chairman, Pres & CEO (Age 67, Pay $1.86M) (LinkedIn Profile)Mr. McDavid Stilwell, Chief Financial Officer (Age 50, Pay $756k) (LinkedIn Profile)Mr. Vladimir Vexler Ph.D., Chief Scientific Officer (Age 64, Pay $778.28k) (LinkedIn Profile)Mr. Richard L. Hameister, Chief Technical OfficerMr. Thomas F. Fitzpatrick, Chief Legal OfficerCheston Turbyfill, VP of CommunicationsMr. Chris Thompson, Exec. VP of SalesMs. Rebecca Sunshine, Exec. VP of HR (Age 59)Mr. Michael A. Fleming, Chief Strategy OfficerMr. Michael Chen, Sr. VP of Commercial Analytics & Trade What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO? 21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Coherus BioSciences' key competitors? Some companies that are related to Coherus BioSciences include Bavarian Nordic A/S (BVNRY), BioCryst Pharmaceuticals (BCRX), Twist Bioscience (TWST), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Krystal Biotech (KRYS), Allogene Therapeutics (ALLO), Immunocore (IMCR), ImmunityBio (IBRX), Recursion Pharmaceuticals (RXRX), Revolution Medicines (RVMD), Valneva (VALN), SpringWorks Therapeutics (SWTX), Exscientia (EXAI) and Vaxcyte (PCVX). View all of CHRS's competitors. What other stocks do shareholders of Coherus BioSciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX). What is Coherus BioSciences' stock symbol? Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS." Who are Coherus BioSciences' major shareholders? Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.59%), State Street Corp (6.67%), Vanguard Group Inc. (6.12%), Peregrine Capital Management LLC (1.22%), Thompson Siegel & Walmsley LLC (0.91%) and Northern Trust Corp (0.91%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler. View institutional ownership trends for Coherus BioSciences. Which major investors are selling Coherus BioSciences stock? CHRS stock was sold by a variety of institutional investors in the last quarter, including Phocas Financial Corp., Eagle Asset Management Inc., Bank of New York Mellon Corp, Citigroup Inc., South Dakota Investment Council, UBS Group AG, Group One Trading L.P., and American Century Companies Inc.. Company insiders that have sold Coherus BioSciences company stock in the last two years include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti, and Vladimir Vexler. View insider buying and selling activity for Coherus BioSciences or view top insider-selling stocks. Which major investors are buying Coherus BioSciences stock? CHRS stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Peregrine Capital Management LLC, Vanguard Group Inc., BlackRock Inc., Thompson Siegel & Walmsley LLC, Renaissance Technologies LLC, Royce & Associates LP, and Sei Investments Co.. View insider buying and selling activity for Coherus BioSciences or or view top insider-buying stocks. How do I buy shares of Coherus BioSciences? Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Coherus BioSciences' stock price today? One share of CHRS stock can currently be purchased for approximately $7.25. How much money does Coherus BioSciences make? Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $561.32 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287.10 million in net income (profit) each year or ($2.730010) on an earnings per share basis. How many employees does Coherus BioSciences have? Coherus BioSciences employs 332 workers across the globe. Does Coherus BioSciences have any subsidiaries? The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..Read More When was Coherus BioSciences founded? Coherus BioSciences was founded in 2010. How can I contact Coherus BioSciences? Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for Coherus BioSciences is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at [email protected]. This page (NASDAQ:CHRS) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here